Viracta Therapeutics (NASDAQ:VIRX) Given “Outperform” Rating at Oppenheimer

Oppenheimer restated their outperform rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a research note released on Wednesday, Benzinga reports. The firm currently has a $13.00 price target on the stock.

Separately, HC Wainwright reissued a buy rating and set a $4.00 price objective on shares of Viracta Therapeutics in a report on Tuesday.

Viracta Therapeutics Trading Up 31.9 %

VIRX stock opened at $0.94 on Wednesday. Viracta Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $2.38. The stock has a fifty day moving average of $0.90 and a 200-day moving average of $0.70.

Viracta Therapeutics (NASDAQ:VIRX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.05). Analysts anticipate that Viracta Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Trading of Viracta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VIRX. Millennium Management LLC purchased a new stake in Viracta Therapeutics during the 2nd quarter worth about $1,227,000. Vanguard Group Inc. lifted its holdings in Viracta Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,114,368 shares of the company’s stock worth $4,759,000 after purchasing an additional 207,108 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Viracta Therapeutics in the 3rd quarter valued at about $625,000. BlackRock Inc. raised its holdings in shares of Viracta Therapeutics by 22.2% in the 3rd quarter. BlackRock Inc. now owns 662,600 shares of the company’s stock valued at $2,830,000 after acquiring an additional 120,169 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Viracta Therapeutics in the 4th quarter valued at about $87,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.